RXRX
Recursion Pharmaceuticals Inc
4.10$
+1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -721.8% | -697.3% | -758.3% | -570.8% | -227.1% | -2,558.9% | -894.9% | -400.0% | -2,267.8% | -129.6% | -1,253.1% | -1,381.3% | -638.9% | |
| 75.0% | 71.1% | 54.7% | 62.3% | 27.6% | 287.1% | 131.1% | 124.8% | 406.6% | 54.8% | 304.0% | 236.9% | 142.9% | |
| 166.2% | 151.4% | 119.5% | 114.7% | 70.0% | 682.4% | 244.5% | 136.9% | 487.8% | 66.9% | 343.2% | 254.2% | 165.4% | |
| -44.2% | -106.1% | -270.2% | -50.9% | -1.0% | 134.1% | -39.7% | 184.0% | -508.1% | 30.1% | -120.6% | -242.0% | -76.5% | |
| 8.2% | 22.8% | 49.3% | 29.0% | 17.5% | 36.5% | 12.4% | 16.5% | 4.7% | 3.5% | 5.2% | 25.5% | 6.9% | |
| -3.4% | -23.4% | -49.3% | -29.0% | -17.5% | 6,106.3% | -49.3% | -30.4% | -49.3% | -3.5% | -5.2% | -25.5% | -11.1% | |
| – | – | – | – | -8.8% | -46.6% | -13.9% | -10.9% | -41.1% | -6.1% | -34.1% | -29.3% | -16.0% | |
| 532.2% | 759.2% | 103.0% | 1,826.7% | 63.1% | 235.8% | 274.9% | 511.2% | 4,856.8% | 371.5% | -53.6% | -16.5% | 690.2% | |
| -194.2% | 39.7% | -706.2% | 1,226.1% | -179.9% | 3,706.3% | -636.6% | 129.2% | 2,575.8% | 244.2% | -1,371.2% | -1,412.8% | 41.9% | |
| -730.0% | -720.0% | -807.6% | -599.8% | -244.6% | -2,595.4% | -907.4% | -416.5% | -2,272.5% | -133.1% | -1,258.3% | -1,406.9% | -645.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.